The company had announced the expected date of completion of sale and disposal of the said undertaking is 90 days from the date of signing the Definitive Agreements.
The company plans to aggressively invest in longer gestation period projects like innovation, biosimilars, vaccines, etc.
The deal is to sell one of the two business undertakings of ZAHL for a lump sum consideration of Rs. 2921 crores on a cash free and debt free basis,
Both the vaccines have been extensively tested by IVRI for safety and potency and have been found to provide 100% protection
The results were consistent across both the 10 mg and 40 mg treatment arms
The early-stage study will test the drug’s safety, tolerability and biological effects in humans
Their findings, published in the journal Nature, reveal that the spines’ unique porous internal structure allows them to convert water movement into measurable electrical signals
The company has commissioned a new plant at Khanna (Punjab), which has begun commercial production
Subscribe To Our Newsletter & Stay Updated
